Scandion Oncology receives final approval from the Danish Medicines Agency and Ethical Committee for start of a clinical trial in patients with pancreatic cancer

Scandion Oncology A/S (“Scandion Oncology”) today announces that the company has received final approval from the Danish Medicines Agency and Ethical Committee to initiate a clinical trial with the drug candidate SCO-101 in combination with first line chemotherapy in patients with inoperable or metastatic pancreatic cancer. This is the second clinical trial with SCO-101 that will commence in 2020. Results from this trial are expected in Q2-Q3, 2021

The release as fetched from its publisher. scandiononcology.com ↗